Grace Therapeutics (GRCE) Competitors $3.09 +0.02 (+0.65%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRCE vs. ENTA, SCLX, FTLF, NLTX, KYTX, AARD, BIOA, TVGN, CLLS, and VTYXShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Enanta Pharmaceuticals (ENTA), Scilex (SCLX), FitLife Brands (FTLF), Neoleukin Therapeutics (NLTX), Kyverna Therapeutics (KYTX), Aardvark Therapeutics (AARD), BioAge Labs (BIOA), Tevogen Bio (TVGN), Cellectis (CLLS), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Enanta Pharmaceuticals Scilex FitLife Brands Neoleukin Therapeutics Kyverna Therapeutics Aardvark Therapeutics BioAge Labs Tevogen Bio Cellectis Ventyx Biosciences Enanta Pharmaceuticals (NASDAQ:ENTA) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Is ENTA or GRCE more profitable? Grace Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -141.98%. Grace Therapeutics' return on equity of -20.36% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-141.98% -89.02% -27.28% Grace Therapeutics N/A -20.36%-18.09% Which has more volatility & risk, ENTA or GRCE? Enanta Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Which has stronger valuation & earnings, ENTA or GRCE? Grace Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$67.64M2.35-$116.04M-$4.32-1.72Grace TherapeuticsN/AN/A-$9.57M-$0.86-3.59 Do analysts prefer ENTA or GRCE? Enanta Pharmaceuticals presently has a consensus target price of $20.20, indicating a potential upside of 171.14%. Grace Therapeutics has a consensus target price of $12.00, indicating a potential upside of 288.35%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ENTA or GRCE? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ENTA or GRCE? In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.41 beat Enanta Pharmaceuticals' score of 0.42 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGrace Therapeutics beats Enanta Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.45M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E RatioN/A21.3075.8626.51Price / SalesN/A379.77489.92165.26Price / CashN/A44.4425.8129.89Price / Book0.649.6112.846.32Net Income-$9.57M-$53.28M$3.28B$270.51M7 Day Performance-5.21%0.31%0.22%2.15%1 Month Performance-5.21%4.58%4.61%6.35%1 Year PerformanceN/A9.24%68.33%25.48% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.902 of 5 stars$3.09+0.7%$12.00+288.3%N/A$42.45MN/A0.00N/ANews CoverageAnalyst UpgradeENTAEnanta Pharmaceuticals4.1536 of 5 stars$8.66+4.0%$22.25+156.9%-40.0%$178.08M$67.64M-2.00160News CoveragePositive NewsAnalyst ForecastSCLXScilex2.2017 of 5 stars$25.36-0.2%$455.00+1,694.2%-36.1%$176.85M$56.59M-0.8780FTLFFitLife Brands4.2179 of 5 stars$18.13-2.7%$23.00+26.9%+10.2%$175.05M$64.47M21.5820Positive NewsNLTXNeoleukin TherapeuticsN/A$18.60-3.4%N/A-54.7%$174.80MN/A-5.9890KYTXKyverna Therapeutics2.8759 of 5 stars$4.15+3.2%$16.60+300.0%-45.7%$173.85M$7.03M-1.1396News CoveragePositive NewsAARDAardvark Therapeutics3.6618 of 5 stars$7.79-2.6%$32.60+318.5%N/A$173.57MN/A0.0018Positive NewsGap UpHigh Trading VolumeBIOABioAge Labs0.2063 of 5 stars$4.91+1.9%N/AN/A$172.80MN/A0.00N/ANews CoverageTVGNTevogen Bio2.4642 of 5 stars$0.88+1.3%$10.00+1,031.6%+75.8%$171.62MN/A0.003CLLSCellectis3.352 of 5 stars$2.98-2.3%$4.00+34.2%+32.9%$169.53M$49.22M-3.63290Positive NewsShort Interest ↓Gap UpHigh Trading VolumeVTYXVentyx Biosciences2.5578 of 5 stars$2.38+0.4%$7.50+215.1%+0.4%$169MN/A-1.4230Positive News Related Companies and Tools Related Companies Enanta Pharmaceuticals Alternatives Scilex Alternatives FitLife Brands Alternatives Neoleukin Therapeutics Alternatives Kyverna Therapeutics Alternatives Aardvark Therapeutics Alternatives BioAge Labs Alternatives Tevogen Bio Alternatives Cellectis Alternatives Ventyx Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRCE Stock Alerts